Alexander Drilon MD
@alexdrilon
Chief, Early Drug Development Service; Associate Attending Physician, Thoracic Oncology Service; Memorial Sloan Kettering Cancer Center
ID:389758857
https://www.mskcc.org/cancer-care/doctors/alexander-drilon 12-10-2011 23:21:19
170 Tweets
4,2K Followers
227 Following
Two research technician positions are immediately available in my lab Johns Hopkins Medicine Johns Hopkins Kimmel Cancer Center. You will be working on KRAS targeting in solid cancer. If interested, please apply here:
jobs.jhu.edu/job/Baltimore-…
jobs.jhu.edu/job/Baltimore-…
Don’t miss out on the opportunity to join the lab of the fabulous Dr. Misale. Our phase I team is absolutely excited to continue working with her. Congratulations Sandra Misale!!
Out today in Cancer Discovery our new work where we describe the genetic bases of acquired resistance to EGFR/KRAS G12C dual blockade in colorectal cancer. Here’s the link of the paper shorturl.at/EOPT8 and a thread👇:
Hello, 3rd ed! The print version is out in a few weeks. The digital version is available now on Kindle and other e-readers. Congratulations to Noura Choudhury, MD Yonina Murciano-Goroff Neil Vasan Lab and the many contributing authors!! amazon.com/gp/aw/d/B0B9T5…
Aaaaand we're back!! 9 years really flew by since I was last here while working at #MSKCC ; now as a #HOfellow Cleveland Clinic. Especially humbled to reconnect with a close friend and AMAZING mentor Alexander Drilon MD at #ASCO22 !!
Quick recap of today's presentation of Zeno in heavily pretreated NRG1+ solid tumors. Efficacy observed across tumor types with ORR of 42% in PDAC. Thanks to ASCO for the opportunity to present, Ignacio Garrido-Laguna for an excellent discussion, collaborators, and patients. #ASCO2021
Congratulations to Noura Choudhury, MD on her Conquer Cancer, the ASCO Foundation ASCO Young Investigator Award. I'm lucky to co-mentor her with Helena Yu . She has an interesting trial combining amivantamab and lazertinib in patients with EGFR mutant NSCLC progressing in the CNS (almost open!).
RETpositive has officially launched! We are a patient-led coalition formed to advance research on RET+ cancers. Through our partnership with LUNGevity Foundation and a generous donation-matching program, we hope to fund lifesaving research. Join us at retpositive.org #RETcancer
A call for rational type II TKI development. Seen through the lens of next-gen TRK inhibitor resistance in TRK fusion+ cancers. 🤓Highlights the utility of TKI type switching as a strategy for on-target resistance in oncogene-driven tumors. Emiliano Cocco Maurizio Scaltriti
Excited to chair a free online lung cancer OncLive.com webinar with Benjamin Levy covering the latest topics in management of #NSCLC Wednesday, October 14, 6:30pm EST featuring expert faculty: Alexander Drilon MD I.DagogoJackMD Joshua Reuss @kamarrone #LCSM
event.onclive.com/d/q7qppz
Our paper is officially out on this month's Cancer Discovery issue! Looking forward to seeing these results translated to clinic! Elizabeth McKenna Alberto Bardelli @sloan_kettering